STRESS DEGRADATION OF LISINOPRIL DIHYDRATE IN DIFFERENT AQUEOUS MEDIA
Lisinopril is an antihypertensive drug from the ACE inhibitor group. It is often used in practice and, in oral administration is characterized by very low percentage of resorption (~25%). Therefore, it is important to ensure the stability of this drug, since any degradation leads to a decrease in the percentage of resorption and an increased risk of sub-dosage of patients. In accordance with modern trends of pharmaceutical analysis, the chemical stability of lisinopril under the influence of various aqueous media was tested: distilled water, 0.1M HCl, 0.1M and 0.01M NaOH and 3% hydrogen peroxide solution. In order to clearly define the effect of elevated temperature on the stability of this drug, tests were carried out at 25 °C and 50 °C. High-pressure liquid chromatography was used as the method for stability testing. The obtained results clearly define that lisinopril is the most sensitive to hydrolysis in the base environment, where at 25 °C, in the first minute, it degrades ~100%. In this paper, kinetic parameters (degradation constant rate, half-life of degradation, order kinetics, and activation energy) were also determined, which enabled clear definition of the stability and identification of degradation products of lisinopril under the influence of various stress agents. In the degradation of lisinopril in neutral and acidic medium, impurity D is identified as the main degradation product.
P. J. Jansen, W. K. Smith, S. W. Baertschi, Stress testing: Analytical considerations - pharmaceutical stress testing predicting drug degradation, Taylor and Francis group, Boca Raton, 2005, 142−72.
K. M. Alsante, A. Ando, R. Brown, J. Ensing, T. D. Hatajik, W. Kong, The role of degradant profiling in active pharmaceutical ingredients and drug products - Advanced drug delivery reviews, Vol. 59−1 (2007) 29−37.
ICH Harmonised tripartite Guideline, Stability testing of new drug substance and products. ICH Q1A (R2), curent step 4 version 2003.
Organization WH, Stability testing of active pharmaceutical ingredients and finished pharmaceutical products. WHO Technical Report Series, No 953 (2009) 87−123.
H. Hafez, A. Elshanawany, L. Abdelaziz, M. Mohram, Development of a stability-indicating HPLC method for simultaneous determination of amlodipine besylate and atorvastatin calcium in tablets, Austin Journal of Analytical and Pharmaceutical Chemistry, Vol. 1−6 (2014) 1028−1036.
S. Ahuja, Overview of modern pharmaceutical analysis, Handbook of modern pharmaceutical analysis, Vol. 10 (2010) 1−5.
K. Huynh-Ba, Handbook of stability testing in pharmaceutical development: regulations, methodologies, and best practices, Springer Science & Business Media, 2008, 9−93.
S. P. Stodghill, Thermal analysis - a review of techniques and applications in the pharmaceutical sciences, American Pharmaceutical Review, Vol. 13−2 (2010) 29−47.
P. J. Haines, Thermal methods of analysis: principles, applications and problems, Springer Science & Business Media, 2012, 1−21.
N. Sultana, M. S. Arayne, R. Siddiqui, S. Naveed, RP-HPLC method for the simultaneous determination of lisinopril and NSAIDs in API, pharmaceutical formulations and human serum, American Journal of Analytical Chemistry, Vol. 3−2 (2012) 147−54.
E. H. Adam, Stress degradation studies on lisinopril dihydrate using modified reverse phase high performance liquid chromatography, American Journal of Analytical Chemistry, Vol. 5−5 (2014) 316−325.
M. de Diego, J. Soto, S. Mennickent, Stability-indicating LC method for the simultaneous determination of lisinopril and hydrochlorothiazide, Journal of Chromatographic Science, Vol. 52−10 (2013) 1193−1197.
N. M. Rao, D. Gowrisankar, Stability-indicating HPLC method for simultaneous determination of atenolol, aspirin, lisinopril and simvastatin in bulk and tablets, Indian Journal of Pharmaceutical Sciences, Vol. 78−2 (2016) 217−223.
C. A. Beasley, J. Shaw, Z. Zhao, R. A. Reed, Development and validation of a stability indicating HPLC method for determination of lisinopril, lisinopril degradation product and parabens in the lisinopril extemporaneous formulation, Journal of Pharmaceutical and Biomedical analysis, Vol. 37−3 (2005) 559−567.
Z. A. W. Gul, S. Khan, K. Saeed, H. Raees, Methods of analysis of lisinopril: A Review, Journal of Bioequivalence and Bioavailability, Vol. 9 (2017) 1−4.
S. T. Tuse, D. S. Musmade, V. S. Kasture, Stress degradation of lisinopril as per ICH Guidelines & Characterisation, International Journal of Advances in Pharmaceutical Analysis, Vol. 4−2 (2014) 47−52.
MarvinSketch − used for the characterization of the chemical structures of the test compounds, Version 15.4.13, 2015, ChemAxon, Hungary. (http://www.chemaxon.com), Last access 27.12.2017.
European Pharmacopoeia 8th Edition Council of Europe, Strasbourg 2014.